{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:58:25Z","timestamp":1761469105245,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.transci.2021.103302","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:23:23Z","timestamp":1635481403000},"page":"103302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-3473","authenticated-orcid":false,"given":"Alieh","family":"Fazeli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahin","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehran","family":"Bahraini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-1176","authenticated-orcid":false,"given":"Ali","family":"Arabkhazaeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooshin","family":"Jelveh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Eshghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2021.103302_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.transci.2021.103302_bib0010","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fphar.2020.572870","article-title":"Potential therapeutic options for COVID-19: current status, challenges, and future perspectives","volume":"11","author":"Sarkar","year":"2020","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.transci.2021.103302_bib0015","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.transci.2021.103302_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1016\/j.transci.2021.103302_bib0025","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1097\/CCM.0b013e3181d44c1e","article-title":"Hark back: passive immunotherapy for influenza and other serious infections","volume":"38","author":"Luke","year":"2010","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.transci.2021.103302_bib0030","first-page":"152","article-title":"Convalescent plasma: new evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfusion"},{"issue":"1","key":"10.1016\/j.transci.2021.103302_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2021.103302_bib0040","article-title":"Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals","author":"Zost","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.transci.2021.103302_bib0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.transci.2021.103302_bib0050","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.transci.2021.103302_bib0055","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/S2352-3026(20)30117-4","article-title":"The resurgence of convalescent plasma therapy","volume":"7","author":"The Lancet Haematology","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.transci.2021.103302_bib0060","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/cid\/ciaa721","article-title":"Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients","volume":"71","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.transci.2021.103302_bib0065","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02005-20","article-title":"Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients","volume":"58","author":"Luchsinger","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.transci.2021.103302_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100525","article-title":"Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma","volume":"26","author":"Maor","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.transci.2021.103302_bib0075","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.transci.2021.103302_bib0080","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/trf.14530","article-title":"Characterization of source plasma from self\u2010identified vaccinated or convalescent donors during the 2009 H 1 N 1 pandemic","volume":"58","author":"Khalenkov","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2021.103302_bib0085","first-page":"1","article-title":"Considering how biological sex impacts immune responses and COVID-19 outcomes","volume":"11","author":"Scully","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.transci.2021.103302_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmolb.2020.00157","article-title":"Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.transci.2021.103302_bib0095","first-page":"11","article-title":"Geographical distribution of ABO and Rh (D) blood groups among Iranian blood donors in the year 1361 (1982) as compared with that of the year 1380 (2001)","volume":"1","author":"Pourfathollah","year":"2004","journal-title":"Scientific Journal of Iran Blood Transfus Organ"},{"issue":"12","key":"10.1016\/j.transci.2021.103302_bib0100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/glycob\/cwn093","article-title":"Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies","volume":"18","author":"Guillon","year":"2008","journal-title":"Glycobiology"},{"key":"10.1016\/j.transci.2021.103302_bib0105","article-title":"Testing the association between blood type and COVID-19 infection, intubation, and death","author":"Zietz","year":"2020","journal-title":"MedRxiv"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050221003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:54:09Z","timestamp":1761468849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050221003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1473050221003025"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2021.103302","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2021.103302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103302"}}